Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Diabetes mellitus is a prevalent metabolic disorder characterized by reduced insulin activity leading to hyperglycemia, affecting over 425 million people globally. Traditional treatments, including sulfonylureas and biguanides, often have undesirable side effects, prompting a shift toward herbal remedies for diabetes management and prevention.

Objective: This study aims to evaluate the antidiabetic effects of budding leaves from compared to metformin in preventing streptozotocin (STZ)-induced hyperglycemia in rats.

Materials And Methods: An study was conducted using adult male Wistar albino rats. STZ was administered on day 15 and was followed till day 18. Methanolic extract of (MECI) at different dosages (250, 500, and 1000 mg), metformin (500 mg), and normal saline were administered to different groups of rats. Blood glucose levels (at day 1, 15, and 18) and biochemical parameters (lipid profile, hepatic and renal parameters, and oxidative stress markers) were measured at days 1 and 18. At the end, a histopathological examination of the pancreas, liver, and kidney was done. Statistical analyses were performed to determine significance.

Results: The study found that while the MECI at 500 mg/kg showed a significant reduction in blood glucose levels compared to the diabetic control group ( < 0.0001), it was less effective than metformin ( > 0.05). Higher doses of MECI demonstrated potential in improving liver and renal parameters ( < 0.0001), as well as reducing oxidative stress ( < 0.0001) compared to metformin indicating its beneficial effects in diabetic conditions.

Conclusion: shows promise as an adjunctive therapy for the prevention of diabetes due to its multifaceted mechanisms, including enhancing insulin secretion and reducing oxidative stress. However, further clinical trials are needed to confirm these findings and establish optimal dosages.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058047PMC
http://dx.doi.org/10.4103/ijabmr.ijabmr_580_24DOI Listing

Publication Analysis

Top Keywords

compared metformin
12
oxidative stress
12
methanolic extract
8
blood glucose
8
glucose levels
8
renal parameters
8
reducing oxidative
8
metformin
5
evaluation antidiabetic
4
antidiabetic potential
4

Similar Publications

The purpose of this study was to investigate the efficacy and safety of add-on metformin treatment in persons with active epilepsy (a-PWE). This is a single-centric, double-blind, placebo-controlled trial randomised a-PWE (1:1) to receive either metformin (extended-release 500 mg) or matching placebo for 6 months along with background antiseizure medications. Primary outcome was percentage change in seizure frequency/month, and secondary outcomes were 50% responder rate, serum mTOR expression, and serum total antioxidant capacity (TAC), body composition analysis, quality of life (QOL), and safety assessment.

View Article and Find Full Text PDF

Purpose: To assess the effect of empagliflozin on the expression of SGLT-2 and GLUT-1 in the chorioretina of streptozotocin-induced diabetic rats.

Methods: An experimental study was performed on Wistar rats. After a 2-week adaptation period, the rats were allocated to one of four groups.

View Article and Find Full Text PDF

Aim: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea.

Materials And Methods: This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial. Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.

View Article and Find Full Text PDF

Introduction: This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA).

Methods: The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis.

View Article and Find Full Text PDF

Background: Emerging evidence indicates that metformin-based combination therapy may offer better glycemic control and improved tolerability compared to diabetes monotherapy. Building on this, vitamin D was considered a potential adjunct to metformin for managing type 2 diabetes. Although vitamin D is primarily recognized for its role in calcium regulation, it also appears to influence glucose metabolism and other non-skeletal functions.

View Article and Find Full Text PDF